Towards Personalized Chemotherapy in Gastrointestinal Cancers: Prospective Analysis of Pharmacogenetic Variants in a Russian Cohort
Authors:
- Denis FedorinovDFDenis Fedorinov
- Vladimir LyadovVladimir Lyadov
- Marina LyadovaMLMarina Lyadova
- Sherzod AbdullaevSASherzod Abdullaev
- Anastasia KachanovaAKAnastasia Kachanova
- Rustam HeydarovRHRustam Heydarov
- Igor ShashkovISIgor Shashkov
- Sergey SurzhikovSSSergey Surzhikov
- Vladimir MikhailovichVMVladimir Mikhailovich
- Dmitry SychevDSDmitry Sychev
Open Access
Abstract
Background/Objectives: Pharmacogenetic variability plays a crucial role in determining both the efficacy and toxicity of chemotherapy for gastrointestinal cancers. However, data on allele frequencies and their clinical relevance in Russian populations remain scarce. Methods: We conducted a prospective observational study of 412 patients with gastrointestinal malignancies between 2020 and 2023. Pharmacogenetic testing was performed prior to the initiation of chemotherapy using real-time allele-specific PCR and microarray hybridization technology. Polymorphisms in the DPYD, UGT1A1, CYP2C8, CYP3A5, GSTP1, ERCC1, XPC, CDA, MTHFR, TYMS, and SLC31A1 genes were analyzed. Results: The frequency of most variants was consistent with those reported in European populations, reflecting the ethnic proximity of the studied cohort. Several clinically relevant variants were identified: DPYD rs2297595 occurred more frequently than in European cohorts, and UGT1A1 rs8175347 was observed at a higher prevalence, underscoring the potential risk of irinotecan-related neutropenia and diarrhea. CYP2C8 rs10509681 was present at frequencies comparable to European populations and is associated with an increased risk of taxane-induced peripheral neuropathy. Other markers (GSTP1, ERCC1, CDA, SLC31A1, MTHFR, TYMS) demonstrated variable associations with chemotherapy efficacy and toxicity, consistent with findings from previous international studies. Conclusions: This study provides the first comprehensive description of pharmacogenetic polymorphisms in a Russian cohort of patients with gastrointestinal cancers. Our findings confirm the clinical importance of DPYD and UGT1A1 testing and highlight additional variants of potential interest.Keywords
Funding Information
- Ministry of Science and Higher Education of the Russian Federation (075-15-2025-463)
This publication has 27 references indexed in Scilit:
- Global Burden of 5 Major Types of Gastrointestinal CancerGastroenterology, 2020
- A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapyEuropean Journal of Cancer, 2019
- Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and PharmacogeneticsClinical Pharmacokinetics, 2018
- Advances and challenges in hereditary cancer pharmacogeneticsExpert Opinion on Drug Metabolism & Toxicology, 2016
- Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient dataThe Lancet Oncology, 2015
- Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapyGene, 2015
- Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancerLung Cancer, 2014
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine DosingClinical Pharmacology & Therapeutics, 2013
- CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxelAnnals of Oncology, 2013
- A meta-analysis of DNA repair gene XPC polymorphisms and cancer riskJournal of Human Genetics, 2007